With a buyout, planned spinout and late-stage readouts, GSK promises this will be a landmark year

GlaxoSmithKline CEO Emma Walmsley has the Q1 sales numbers to start off what she says will be a landmark year. But delivering on the rest of the year might not be so easy.

So far, the numbers are in her favor. The UK pharma claimed Q1 sales of just over $12.2 billion, beating out sales estimates that originally placed the pharma’s quarterly sales at around $11.5 billion and up 32% year over year.